SAREPTA THERAPEUTICS, INC. Repayments of Long-term Lines of Credit
SAREPTA THERAPEUTICS, INC. (SRPT) reported Repayments of Long-term Lines of Credit of $235.95 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermLinesOfCredit · last filed 2021-03-01
- SAREPTA THERAPEUTICS, INC. repayments of long-term lines of credit for the quarter ending 2018-12-31 was $17.32M, a 4.12% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. repayments of long-term lines of credit for the quarter ending 2018-09-30 was $44.98M.
- SAREPTA THERAPEUTICS, INC. repayments of long-term lines of credit for the quarter ending 2018-06-30 was $73.51M.
- SAREPTA THERAPEUTICS, INC. repayments of long-term lines of credit for the quarter ending 2018-03-31 was $100.14M.
- SAREPTA THERAPEUTICS, INC. repayments of long-term lines of credit for fiscal 2018 was $235.95M, a 495.17% increase from fiscal 2017.
- SAREPTA THERAPEUTICS, INC. repayments of long-term lines of credit for fiscal 2017 was $39.65M.
| Period end | Repayments of Long-term Lines of Credit 3 month | Repayments of Long-term Lines of Credit 6 month | Repayments of Long-term Lines of Credit 9 month | Repayments of Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2018-12-31 | $17.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $62.30M derived: sum of 2 quarters · filed 2021-03-01 | $135.81M derived: sum of 3 quarters · filed 2021-03-01 | $235.95M 10-K · filed 2021-03-01 |
| 2018-09-30 | $44.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $118.49M derived: sum of 2 quarters · filed 2019-11-07 | $218.63M 10-Q · filed 2019-11-07 | $235.27M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $73.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $173.65M 10-Q · filed 2019-08-07 | $190.29M derived: sum of 3 quarters · filed 2020-02-26 | |
| 2018-03-31 | $100.14M 10-Q · filed 2019-05-08 | $116.78M derived: sum of 2 quarters · filed 2020-02-26 | ||
| 2017-12-31 | $16.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $39.65M 10-K · filed 2020-02-26 | ||
| 2017-09-30 | $23.01M 10-Q · filed 2018-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |